AHA Statement On Eli Lilly Withholding 340B Discounts

Rick Pollack
President and CEO
American Hospital Association

June 18, 2026

AHA can confirm that Eli Lilly has taken the extraordinary action of denying 340B discounts. Congress should immediately use its oversight authority and demand HHS take a position on drug companies’ attempts to hijack the 340B program through burdensome claims-data demands. These manufacturer-imposed requirements would drain scarce resources from 340B hospitals and threaten patients’ access to lifesaving drugs. HRSA and HHS cannot continue to stand by while Eli Lilly and others rewrite the rules for their own benefit and skirt their obligations.

###